MA49896A - Nouveaux analogues d'insuline acylés et leurs utilisations - Google Patents

Nouveaux analogues d'insuline acylés et leurs utilisations

Info

Publication number
MA49896A
MA49896A MA049896A MA49896A MA49896A MA 49896 A MA49896 A MA 49896A MA 049896 A MA049896 A MA 049896A MA 49896 A MA49896 A MA 49896A MA 49896 A MA49896 A MA 49896A
Authority
MA
Morocco
Prior art keywords
insulin analogues
acylated insulin
new acylated
new
analogues
Prior art date
Application number
MA049896A
Other languages
English (en)
Inventor
Jakob Brandt
Bo Falck Hansen
Grith Skytte Olsen
Ingrid Pettersson
Lauge Schäffer
Rita Slaaby
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MA49896A publication Critical patent/MA49896A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/90Fusion polypeptide containing a motif for post-translational modification
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
MA049896A 2017-08-17 2018-08-16 Nouveaux analogues d'insuline acylés et leurs utilisations MA49896A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17186612 2017-08-17
EP17204872 2017-12-01

Publications (1)

Publication Number Publication Date
MA49896A true MA49896A (fr) 2020-06-24

Family

ID=63165388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049896A MA49896A (fr) 2017-08-17 2018-08-16 Nouveaux analogues d'insuline acylés et leurs utilisations

Country Status (19)

Country Link
US (2) US10919949B2 (fr)
EP (1) EP3668892A1 (fr)
JP (2) JP2020531451A (fr)
KR (1) KR20200038502A (fr)
CN (1) CN111032685A (fr)
AU (1) AU2018317810A1 (fr)
BR (1) BR112020002364A2 (fr)
CA (1) CA3071686A1 (fr)
CL (1) CL2020000310A1 (fr)
CO (1) CO2020002500A2 (fr)
IL (1) IL272394A (fr)
MA (1) MA49896A (fr)
MX (1) MX2020001434A (fr)
PE (1) PE20211264A1 (fr)
PH (1) PH12020550050A1 (fr)
RU (1) RU2020108281A (fr)
SG (1) SG11202001077UA (fr)
TW (1) TW201917134A (fr)
WO (1) WO2019034726A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CA3204051A1 (fr) 2021-01-20 2022-07-28 Brian Lian Compositions et procedes pour le traitement de troubles metaboliques et hepatiques
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
WO2024185897A1 (fr) * 2023-03-09 2024-09-12 学校法人神戸学院 Étiquette de fragment d'insuline et composition pharmaceutique

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5616729A (en) 1986-07-17 1997-04-01 Board Of Governors Of Wayne State University Enhanced chemiluminescence from 1,2-dioxetanes through energy transfer to tethered fluorescers
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
DK33591D0 (fr) 1991-02-27 1991-02-27 Novo Nordisk As
IL114160A (en) 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
ES2258797T3 (es) 1996-12-20 2006-09-01 Novo Nordisk A/S Proteinas con extension n-terminal expresadas en la levadura.
WO2000043034A2 (fr) 1999-01-26 2000-07-27 Eli Lilly And Company Formulations d'analogues d'insuline acyles hexameres monodisperses
CA2372393A1 (fr) * 1999-05-19 2000-11-23 Bassil I. Dahiyat Nouvelles proteines a action insulinoide utilisees dans le traitement du diabete
KR20030004317A (ko) 1999-12-29 2003-01-14 노보 노르디스크 에이/에스 인슐린 선구물질 및 인슐린 선구물질 유사체의 제조 방법
EP1692168B1 (fr) 2003-12-03 2011-07-20 Novo Nordisk A/S Insuline monocatenaire
WO2006008238A1 (fr) 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
EP2256130B1 (fr) 2005-02-02 2013-09-25 Novo Nordisk A/S Nouveaux dérivés d'insuline
DE602007009496D1 (de) * 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
RU2524150C2 (ru) 2006-09-22 2014-07-27 Ново Нордиск А/С Аналоги инсулина, устойчивые к протеазам
US9150633B2 (en) 2007-08-15 2015-10-06 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
WO2009112583A2 (fr) 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376099A4 (fr) 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp Facteurs de croissance semblables à l'insuline à base d'yl exprimant une haute activité au récepteur de l'insuline
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン類似体
US20120241356A1 (en) 2009-07-06 2012-09-27 Sanofi-Aventis Deutschland Gmbh Heat- and vibration-stable insulin preparations
WO2011159882A2 (fr) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Nouveaux agonistes stabilisés de l'insuline
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
JP5973427B2 (ja) 2010-06-23 2016-08-23 ノヴォ ノルディスク アー/エス 追加のジスルフィド結合を含有するインスリン類似体
WO2011163460A1 (fr) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Facteurs de croissance insulinomimétiques à base d'yl à activité élevée sur le récepteur de l'insuline
EP2585102B1 (fr) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Promédicaments insuliniques à base d'amide
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
WO2012049307A2 (fr) 2010-10-15 2012-04-19 Novo Nordisk A/S Nouveaux dérivés d'insuline à extrémité n modifiée
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
US20140357838A1 (en) 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
EP3395358B1 (fr) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Dimères d'un analogue d'insuline
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
US10421795B2 (en) 2012-12-17 2019-09-24 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation インスリン‐インクレチン複合物
CN105392475A (zh) 2013-07-24 2016-03-09 诺和诺德股份有限公司 包含片剂核和阴离子共聚物涂层的用于口服胰岛素给药的药学组合物
KR20160065930A (ko) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 글루코스-반응성 인슐린 접합체
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
TN2017000178A1 (en) 2014-11-21 2018-10-19 Merck Sharp & Dohme Insulin receptor partial agonists
WO2016119854A1 (fr) 2015-01-29 2016-08-04 Novo Nordisk A/S Composition pharmaceutique pour l'administration d'insuline par voie orale comprenant un noyau de comprimé et un enrobage d'alcool polyvinylique
US10562951B2 (en) 2015-03-10 2020-02-18 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
US20180110863A1 (en) 2015-04-08 2018-04-26 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
WO2016172269A2 (fr) 2015-04-20 2016-10-27 University Of Utah Research Foundation Analogues d'insuline ayant des peptides à chaîne b raccourcie et procédés associés
CN108368163A (zh) * 2015-08-25 2018-08-03 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
US20190010206A1 (en) * 2015-08-25 2019-01-10 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
EP3344651B1 (fr) 2015-09-02 2022-03-02 Merck Sharp & Dohme Corp. Procédé d'obtention d'insuline avec liaisons disulfure correctement formées

Also Published As

Publication number Publication date
PE20211264A1 (es) 2021-07-15
RU2020108281A3 (fr) 2022-03-09
CO2020002500A2 (es) 2020-06-09
RU2020108281A (ru) 2021-08-26
CL2020000310A1 (es) 2020-07-10
PH12020550050A1 (en) 2020-10-19
AU2018317810A1 (en) 2020-03-19
US10919949B2 (en) 2021-02-16
IL272394A (en) 2020-03-31
JP2020531451A (ja) 2020-11-05
US20190194285A1 (en) 2019-06-27
JP2022105082A (ja) 2022-07-12
US20210094999A1 (en) 2021-04-01
WO2019034726A1 (fr) 2019-02-21
BR112020002364A2 (pt) 2020-09-01
CA3071686A1 (fr) 2019-02-21
MX2020001434A (es) 2020-03-20
SG11202001077UA (en) 2020-03-30
CN111032685A (zh) 2020-04-17
KR20200038502A (ko) 2020-04-13
EP3668892A1 (fr) 2020-06-24
TW201917134A (zh) 2019-05-01

Similar Documents

Publication Publication Date Title
MA51288A (fr) Analogues d'incrétine et leurs utilisations
FR25C1018I2 (fr) Éthers d'aryle et leurs utilisations
MA49896A (fr) Nouveaux analogues d'insuline acylés et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA53652A (fr) Lipides peg de haute pureté et leurs utilisations
EP2968443A4 (fr) Analogues d'hepcidine et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
DK3506909T3 (da) 4'-phosphatanaloger og oligonukleotider omfattende samme
EP3307766A4 (fr) Protéine d'interleukine-7 modifiée et ses utilisations
EP3397757A4 (fr) Nouvelles transposases associées à crispr et leurs utilisations
EP3337470A4 (fr) Conjugués d'aldéhyde et leurs utilisations
EP3727371A4 (fr) Inhibiteurs d'hétéromères gpcr et leurs utilisations
EP3359644A4 (fr) Nouvelles nucléases guidé par l'arn et leurs utilisations
EP3349802A4 (fr) Dendrimères lipocationiques et leurs utilisations
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3341404A4 (fr) Nouveaux analogues d'insuline et leur utilisation
EP3302490A4 (fr) Inhibiteurs d'autotaxine et leurs utilisations
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
EP3291676A4 (fr) Analogues de la mitragynine et leurs utilisations
EP3475449A4 (fr) Étalons d'acide nucléique acellulaire et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
EP3347020A4 (fr) Acétamide thiénotriazoldiazépines et leurs utilisations
EP3436434A4 (fr) Analogues d'indoline et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3351533A4 (fr) Dérivé biaryle et médicament le contenant